演題詳細

一般口演 / Oral Session

一般口演 7 (Oral Session 7) :MDS:臨床 1

print

日程
2013年10月11日(金)
時間
09:30 - 10:30
会場
第6会場 / Room No.6 (ロイトン札幌 2F エンプレス)
座長・司会
南谷 泰仁 (Yasuhito Nannya):1
1:東京大学 血液・腫瘍内科
 
前へ戻る

Comparison of the predictive values of IPSS-R and other prognostic scores in MDS patients

演題番号 : OS-1-31

金政 佑典 (Yusuke Kanemasa):1、新谷 直樹 (Naoki Shingai):1、池川 俊太郎 (Shuntaro Ikegawa):1、高橋 幸江 (Yukie Takahashi):1、吉岡 康介 (Kosuke Yoshioka):1、青木 淳 (Jun Aoki):1、安永 愛 (Megumi Yasunaga):1、梅澤 佳央 (Yoshio Umezawa):1、押川 学 (Gaku Oshikawa):1、小林 武 (Takeshi Kobayashi):1、土岐 典子 (Noriko Doki):1、垣花 和彦 (Kazuhiko Kakihana):1、大橋 一輝 (Kazuteru Ohashi):1、坂巻 壽 (Hisashi Sakamaki):1

1:Hematology, Tokyo Metropolitan Komagome Hospital, Japan

 

Background: IPSS has been an important standard for assessing prognosis of adult patients with primary MDS. Recently revised IPSS (IPSS-R) has been developed and was shown to possess improved prognostic ability for survival and AML evolution compared with the IPSS. Materials and methods: We retrospectively analyzed 111 patients of primary MDS diagnosed from January 2008 to December 2012. We evaluated the prognostic value of IPSS-R and compared it with other prognostic scores. Results: WHO classification was as follows: 41% RCMD, 16% RAEB-1, 23% RAEB-2, 4% MDS-U, and 17% were RARS, RA or isolated 5q deletion. IPSS risk stratification: 21% low, 39% Int-1, 27% Int-2, and 14% high. WPSS risk stratification: 9% very low, 23% low, 12% intermediate, 38% high, and 17% very high. IPSS-R risk stratification: 11% very low, 26% low, 20% intermediate, 23% high, and 21% very high. Median follow-up period was 16 months. All prognostic systems allowed the identification of survival curves with significant differences among the different categories of risk stratification. IPSS-R application defined OS curves which had a better predictive value than IPSS and WPSS (concordance index =0.73, 0.66 and 0.69, respectively). According to age-adjusted IPSS-R, 2-year OS was 92%, 90%, 81%, 52% and 37% in very low, low, intermediate, high, and very high risk group, respectively (p<0.0001). Conclusions: IPSS-R is confirmed to be a more refined tool to define prognosis of MDS patients compared with the currently used scores.

前へ戻る